PALI director Wei Binxian receives 510,700 RSUs with 3‑year vesting
Rhea-AI Filing Summary
Palisade Bio director Wei Binxian received 510,700 restricted stock units (RSUs) on 10/06/2025. Each RSU converts to one share of common stock when settled, but may be cash-settled if sufficient shares are not reserved under the 2021 Equity Incentive Plan. The RSUs vest in three equal annual installments, each satisfied on the earlier of the next annual meeting of stockholders or the anniversary of 10/06/2025, subject to continuous service.
The reported holding after the grant is 510,700 shares beneficially owned, held directly. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 10/08/2025.
Positive
- Director received a sizable equity award of 510,700 RSUs, aligning interests with shareholders
- Clear vesting schedule: three equal annual installments, providing predictable retention timing
Negative
- RSUs may be cash‑settled if the 2021 Equity Incentive Plan lacks reserved shares, which could avoid share issuance
- Vesting conditioned on continuous service, so forfeiture is possible if the director departs before vesting dates
Insights
Grant is a standard service‑based RSU award with staged vesting.
The award of 510,700 RSUs represents an equity‑based retention mechanism that vests in three equal annual installments tied to continued service and the company’s next annual meeting or the 10/06/2025 anniversary. The grant can be settled in cash if shares are not reserved under the 2021 Equity Incentive Plan, which preserves flexibility for the issuer.
Key dependencies include the plan’s available share reserve and the director’s continued service through each vesting date. Investors can monitor annual meeting timing and future filings showing whether settlement is in stock or cash within the next 12 months.
Director-level grant increases direct beneficial ownership by a clearly quantified amount.
The Form 4 reports direct ownership rising to 510,700 shares following the grant, which is material for assessing insider alignment with shareholders. The filing indicates one reporting person and includes the required signature by an attorney‑in‑fact.
Governance watchers should note the vesting schedule and the issuer’s share reserve status; subsequent Forms 4 or 10‑Q disclosures may show dilution, cash settlement choices, or additional grants over the next 12 months.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 510,700 | $0.00 | -- |
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, which shall be satisfied on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.
